1661854-97-2
1661854-97-2
Chemical Structure
Zipalertinib
Synonym(s): TAS6417; CLN-081
- CAS No.: 1661854-97-2
- Formula:C23H20N6O
- Molecular Weight:396.44
IUPAC Name: (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizin-8-yl)acrylamide
InChIKey: MKCYPWYURWOKST-INIZCTEOSA-N
SMILES: NC1=C2C(N3C(C(C)=C[C@@H](C3)NC(C=C)=O)=C2C4=CC5=CC=CC=C5N=C4)=NC=N1
Biological Activity: Zipalertinib (TAS6417; CLN-081) is a highly effective, orally active and pan-mutation-selective EGFR tyrosine kinase inhibitor with a unique scaffold fitting into the ATP-binding site of the EGFR hinge region, with IC50 values ranging from 1.1-8.0 nM[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Zipalertinib | 99.62% | Zipalertinib (TAS6417; CLN-081) is a highly effective, orally active and pan-mutation-selective EGFR tyrosine kinase inhibitor with a unique scaffold fitting into the ATP-binding site of the EGFR hinge region, with IC50 values ranging from 1.1-8.0 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.75
HY-164392TAS-121 -
Similarity Score 0.60
HY-158064BTK-IN-36 -
Similarity Score 0.57
HY-164694Emupertinib -
Similarity Score 0.51
HY-148594BTK-IN-23 -
Similarity Score 0.50
HY-148585BTK-IN-22 -
Similarity Score 0.50
HY-153160PERK-IN-6 -
Similarity Score 0.49
HY-13820GSK2656157 -
Similarity Score 0.49
HY-10997Ibrutinib -
Similarity Score 0.49
HY-10997AIbrutinib Racemate -
Explore the MedChemAI to find more analogs
References
- [1]. Hasako S, et al. TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations. Mol Cancer Ther. 2018 Aug;17(8):1648-1658. [Content Brief]
- [2]. Hibiki Udagawa, et al. TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations. Mol Cancer Res. 2019 Nov;17(11):2233-2243. [Content Brief]
